What Is Generate Biomedicines, Inc. (GENB) Worth in 2026?
According to the CirclFi Deep Alpha Valuation Engine, Generate Biomedicines, Inc.'s intrinsic value is estimated at a composite fair value of $8.43. Trading at $14.07, the stock is approaching fair value or slight overvaluation (implied return of -40.1%), as 5 of 8 models suggest limited further upside. Model dispersion is worth noting: First Chicago targets $19.43 (+38.1%), versus Regime Cross at $0.53 (-96.2%). This +134.3% range highlights the importance of multi-model analysis rather than relying on any single methodology.
What Do the Models Say About GENB?
8 of 13 models are currently active for GENB. Of these, 3 models suggest upside while 5 models suggest overvaluation. The Bayesian DCF estimates GENB's intrinsic value at $3.84, implying -72.7% downside from the current price. See which stocks rank higher →
How Does GENB Rank in Pharmaceutical Preparations?
Among 431 Pharmaceutical Preparations stocks, GENB ranks #412 by Quality of Company score. CirclFi's QOC score of 2.0/10 evaluates 32 fundamental signals. A score of 2.0 signals below-average fundamentals.
See all Most Undervalued Pharmaceutical Preparations Stocks →
The Pharmaceutical Preparations sector introduces analytical considerations specific to biopharma enterprise businesses. For Generate Biomedicines, Inc., metrics like FDA approval probability provide important context that general-purpose valuation models may underweight.
Is GENB a Value Trap?
The Value Trap algorithm is not active for GENB. The score cross-references apparent undervaluation against fundamental deterioration signals. Browse lowest value-trap stocks →
Multi-Model Methodology
8 of 13 models are active for Generate Biomedicines, Inc.. Moderate coverage provides meaningful perspective. Each model applies a fundamentally different valuation philosophy. See the complete methodology →
According to the CirclFi Deep Alpha Valuation Engine, Generate Biomedicines, Inc. scores 2.0 out of 10 on our 32-signal quality assessment, a weak rating that exhibits fundamental weaknesses that warrant careful scrutiny. The QOC score synthesizes profitability margins, revenue growth reliability, debt management, and capital allocation into a single metric designed to separate durable businesses from statistically cheap ones.
The gap between the most bullish and bearish model spans +134.3% — demonstrating why single-model analysis is dangerous. Browse all stocks with 13-model coverage →
Data Sources & Confidence
Every GENB valuation is built from SEC EDGAR XBRL filings — 700+ standardized financial tags. Macroeconomic context from FRED calibrates discount rates, while GDELT news sentiment feeds into our Sentiment SOTP model. All pipelines run daily. Read the complete data methodology →
Across GENB's 8 active models, average confidence is 2%. Lower confidence may reflect limited history or high volatility.
CirclFi's output is a research starting point, not a buy/sell signal. All data updates daily. Read the full methodology →
Buy with Gumroad